Barbara Binzak Blumenfeld, a member of the FDA practice group in the Washington, DC office, recently published an article in the Food and Drug Law Institute's Update Magazine. The article, entitled "A Renewed FDA Focus on Cell and Tissue Product Regulation," chronicles FDA's historical regulatory approach towards cell and tissue products, such as stem cells, and discusses recent changes to FDA's approach. Barbara has advised a number of clients on the FDA regulatory challenges presented by such products.
The Food and Drug Law Institute was founded in 1949 to provide a forum for discussing food and drug law issues for all FDA-regulated products. FDLI is a not-for-profit 501(c)(3) organization that does not engage in advocacy actions.
To view the full article, click here for the July/August 2016 archives. (Membership Required)